Lege Artis Medicinae

[Checkmate]

dr. SZIGETI Zoltán

NOVEMBER 19, 2006

Lege Artis Medicinae - 2006;16(11)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[In Memoriam Sándor Gerő (1904-1992)]

dr. EMED Alexander

Lege Artis Medicinae

[THE PHENOMENON OF BURNOUT IN VIEW OF THE HUNGARIAN AND INTERNATIONAL LITERATURE]

KOVÁCS Mariann

[There is plethora of international publications on the topic of burnout among health professionals. The most comprehensive study in Hungarian on this issue was written fifteen years ago by psychiatrist Sandor Fekete. In the past fifteen years there has been a growing interest among both the scientific community and the public in studies on health psychology, behavioural sciences, sociology of health and quality of life as well as in the harmful effects of work stress. The first part of the study presents clarification of the concept of burnout, its development, course, assessment and treatment, whereas the second part gives a brief overview of the history of burnout research in the past thirty years with special focus on the most recent international and Hungarian literature, as well as on changes in research trends.]

Lege Artis Medicinae

[Sexual disturbances in hepatological disease]

GYOVAI Gabriella

Lege Artis Medicinae

[A NEW WAY TO TREAT ALLERGIC ASTHMA: ANTI-IGE THERAPY]

MAGYAR Pál

[Immunoglobulin E (IgE) plays a central role in the pathogenesis of the inflammation of the bronchial mucosa and airway hyperreactivity, which in turn produces the symptoms of allergic bronchial asthma. Omalizumab, the recently developed anti-IgE monoclonal antibody binds to the Cε3 region of the IgE molecule and thus prevents binding of the IgE to the surface of FCεRI receptor bearing cells (mast cells, basophils and antigen presenting dendritic cells). In the absence of cell-bound IgE, these cells are not activated and thus do not release inflammatory mediators and proinflammatory cytokines upon allergen exposition. Treatment with omalizumab significantly decreases the number of bronchial mucosal eosinophils and FCεRI positive cells, and the FCεRI receptor expression of the latter. Double blind controlled clinical studies have demonstrated that omalizumab treatment reduces the number of exacerbations and emergency room visits, the β2-agonist requirement and the dose of inhaled steroids, improves exspiratory airflow limitation, asthmatic symptoms and asthma-related quality of life in patients with moderate to severe allergic asthma. Low baseline FEV1, the use of high dose inhaled corticosteroids and a history of emergency asthma treatment in the past year are significant predictors of a better response to omalizumab. Omalizumab is tolerated well by patients. With the exception of local skin reactions, no significant difference in adverse events between patients taking omalizumab and control groups have been reported. According to the GINA (Global Initiative for Asthma) stepwise therapy protocol of asthma, omalizumab is indicated for severe asthmatics whose symptoms can not be controlled by inhaled corticosteroids and long-acting β2 agonists.]

Lege Artis Medicinae

[I Still Have So Much to Do... A Discussion with Éva Csatár MD]

VARGA Brigitta

All articles in the issue

Related contents